
News|Articles|March 23, 2026
Four FDA Actions Reshaping Drug Development in 2026
Author(s)Andy Studna, Senior Editor
In the first months of 2026, the FDA has moved on multiple fronts to modernize how drugs are developed, evaluated, and approved, signaling a broader regulatory shift toward flexibility, mechanism-based evidence, and human-centric science.
Advertisement
Advertisement
Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency is recalibrating its evidentiary standards to align with advances in biology, trial methodology, and technology. Taken together, these actions have meaningful implications for how sponsors design studies, plan nonclinical programs, and engage with regulators across the development lifecycle.
Related to this article

The agency is still accepting applications but is not reviewing or granting new ones, according to Reuters, while HHS says work under the program is ongoing.

In this Q&A, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, discusses why outdated perceptions of APAC sites persist among smaller biotechs, how China’s regulatory reforms have reshaped Phase III startup timelines, and what first-time sponsors need to get right in the region.

A pivotal trial that missed its primary endpoint became the basis for a successful redesign after the team used the data to define the high-risk patients most likely to benefit, showing that setbacks can strengthen development when organizations interrogate the evidence rather than abandon it.

AI can draft a CSR in minutes, but the report only reflects evidence that has already converged, so faster drafting shifts the bottleneck to upstream reconciliation, database-lock readiness, and human accountability rather than shortening the trial itself.

Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.

Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.

Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.
Advertisement
Advertisement

